Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Br J Pharmacol. 2020 Nov;177(21):4990-4994. doi: 10.1111/bph.15138. Epub 2020 Jul 26.
Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid-19) for which there is no effective treatment, so far. ARDS is caused and sustained by an uncontrolled inflammatory activation characterized by a massive release of cytokines (cytokine storm), diffuse lung oedema, inflammatory cell infiltration, and disseminated coagulation. Macrophage and T lymphocyte dysfunction plays a central role in this syndrome. In several experimental in vitro and in vivo models, many of these pathophysiological changes are triggered by stimulation of the P2X7 receptor. We hypothesize that this receptor might be an ideal candidate to target in Covid-19-associated severe pneumonia. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
严重肺炎与急性呼吸窘迫综合征（ARDS）具有几个共同特征，是目前尚无有效治疗方法的 2019 冠状病毒病（COVID-19）发病率和死亡率的主要原因。ARDS 由失控的炎症激活引起并持续存在，其特征是细胞因子（细胞因子风暴）大量释放、弥漫性肺水肿、炎症细胞浸润和弥散性凝血。巨噬细胞和 T 淋巴细胞功能障碍在该综合征中起核心作用。在许多体外和体内实验模型中，这些病理生理变化中的许多都是由 P2X7 受体的刺激引发的。我们假设该受体可能是 COVID-19 相关严重肺炎的理想靶点。
本文是关于 COVID-19 药理学的专题的一部分。要查看本节中的其他文章，请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
